Stake Purchase

PGDx intersects with Innovatus in $42m deal
Johns Hopkins oncology diagnostics spinout PGDx had previously raised approximately $99m.
Allogene tallies up $120m
The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.
Forendo fixes up $4.7m round
Vesalius has provided $4.7m to Forendo Pharma, whose existing shareholders also include Karolinska Development, Novartis, Novo and Merck Group.
Pfizer coughs up funding for Biontech
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Millendo overtakes OvaScience in merger deal
Endocrine disease therapy developer Millendo, spun out of University of Michigan, will merge with publicly-listed OvaScience, raising a further $30m in the process.
Frontier IP prints stake in NTPE
Frontier IP will take a 31.8% shareholding in NTPE, an electronics printing technology spinout from Universidade Nova de Lisboa.
Gadeta glides into Kite partnership
UMC Utrecht spinout Gadeta has partnered cancer drug developer Kite to drive development of its T-cell therapy, allowing Kite to purchase equity from Gadeta's existing shareholders.

Other News

TTTech sells stake to B&C
B&C has acquired a 9% stake in TTTech for an undisclosed sum, guaranteeing that the TU Wien spinout will continue to be majority-owned by Austrian shareholders.
Big deal: QuantumScape fuels up on VW cash
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
Frontier IP tests Cambridge Material
Cambridge Material Testing Solutions has been established to develop software and equipment that let industrial clients assess the condition of their metal assets.
Humacyte engineers $150m deal
Fresenius Medical Care will purchase a 19% stake in Humacyte, which closed a $75m series C round in March 2018.
Beam Therapeutics lasers in on $87m series A
Beam has emerged out of Harvard University with $87m in series A funding to commercialise gene editing technology, with additional research licensed from Broad Institute and Editas Medicine.

Editor's Picks

Big deal: QuantumScape fuels up on VW cash
VW will invest $100m in QuantumScape and form a joint venture with the Stanford spinout to develop batteries for long-range electric vehicles.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg

Login

Not yet subscribed?

See your subscription offers here